Your institution may have access to this item. Find your institution then sign in to continue.
Title
Temozolomide as second or third line treatment of patients with neuroendocrine carcinomas.
Authors
Olsen, Ingrid H; Sørensen, Jens B; Federspiel, Birgitte; Kjaer, Andreas; Hansen, Carsten P; Knigge, Ulrich; Langer, Seppo W
Abstract
Knowledge of the clinical efficacy in recurrent neuroendocrine carcinomas is sparse. Treatment with temozolomide alone or in combination with capecitabine and bevacizumab has recently shown promising results.